This is the authors' abstract. We don't add key points for this paper.
To the editor: Here we present a case of a patient with JAK2V617F- and IDH2-mutation–positive myelofibrosis (MF) with elevated blasts on ruxolitinib therapy for 8 years with a complete hematologic, histomorphologic, cytogenetic, and molecular remission. MF is a rare Philadelphia chromosome–
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Masárová et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: